Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anthrax test kits

This article was originally published in The Tan Sheet

Executive Summary

Columbus, Ohio-based Toxicology Associates is barred from selling, advertising anthrax nasal swab test kits to Pennsylvania residents under a state court judge's Nov. 18 order. Firm, which sells the $65 kits through its Web site, 1toxassociates.com, also must pay restitution to commonwealth consumers who purchased the anthrax test kits and request a refund through AG's office by Feb. 13, and must pay $5,000 in civil penalties, $2,265 in litigation costs. In an April complaint, AG alleged company violated Unfair Trade Practices & Consumer Protection Law by representing that its tests can determine whether consumers have contracted anthrax. Commonwealth points to CDC guidelines that state nasal swab cultures should not be used to diagnose anthrax; AG also notes firm is not a federally certified facility that can positively confirm presence of anthrax. Company did not file an answer to the lawsuit, AG's office says...

You may also be interested in...



‘We Need Your COVID-19 Testing capacity’ UK Health Secretary Tells Life Science Firms

The UK has an “excellent but small diagnostics industry,” so it needs further testing support from related life science industries to tackle the COVID-19 crisis. One of the outcomes of this could be the creation of new big diagnostics industry players.

Drug/Device Combinations: New Position Paper Explains Notified Body Responsibilities

Medicinal products authorities will consider a medtech notified body opinion on the device element of a drug/device combination product. A new position paper explains how roles and responsibilities are shared between medtech and medicinal product experts.

GC Pharma Aiming To Outrun Rivals For COVID-19 Plasma Therapy

A South Korean pharma firm is set to soon begin pivotal clinical trials for a hyperimmune globulin for the treatment of COVID-19 patients and plans to commercialize the product this year, with a hope of outrunning rivals including Takeda.

Topics

UsernamePublicRestriction

Register

PS094890

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel